Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBT Margin: 2019-2025

Historic EBT Margin for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to -41.92%.

  • Biodesix's EBT Margin rose 1666.00% to -41.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -49.85%, marking a year-over-year increase of 1658.00%. This contributed to the annual value of -59.95% for FY2024, which is 4370.00% up from last year.
  • According to the latest figures from Q3 2025, Biodesix's EBT Margin is -41.92%, which was up 27.77% from -58.03% recorded in Q2 2025.
  • Biodesix's EBT Margin's 5-year high stood at -21.60% during Q1 2021, with a 5-year trough of -238.21% in Q1 2022.
  • For the 3-year period, Biodesix's EBT Margin averaged around -78.31%, with its median value being -60.26% (2025).
  • As far as peak fluctuations go, Biodesix's EBT Margin soared by 17,226bps in 2021, and later crashed by 21,661bps in 2022.
  • Over the past 5 years, Biodesix's EBT Margin (Quarterly) stood at -182.38% in 2021, then spiked by 1,125bps to -171.13% in 2022, then surged by 10,841bps to -62.71% in 2023, then surged by 2,159bps to -41.12% in 2024, then soared by 1,666bps to -41.92% in 2025.
  • Its EBT Margin was -41.92% in Q3 2025, compared to -58.03% in Q2 2025 and -60.26% in Q1 2025.